Literature DB >> 20495831

Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia.

Uri S Alon1, René G VandeVoorde.   

Abstract

We describe a child with familial hypocalciuric hypercalcemia (FHH) in whom the hypercalcemia seemed to interfere with tissue healing after tympanoplasty. Consequently, he was placed on cinacalcet (30 mg/day), changed after 2 weeks to 60 mg/day. The treatment resulted in a decrease in serum parathyroid hormone (PTH) from 148 to 32 pg/mL (normal 7-75) and ionized calcium from 1.48 to 1.23 mmol/L (1.13-1.34), as well as successful healing of the revised surgical scar. Over the 12-month treatment period no complications were noted. We conclude that cinacalcet may be considered a new, and currently the only, tool in treating children with symptomatic FHH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495831     DOI: 10.1007/s00467-010-1547-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  17 in total

1.  The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.

Authors:  Dolores M Shoback; John P Bilezikian; Stewart A Turner; Laura C McCary; Matthew D Guo; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

2.  Calcimimetics--fooling the calcium receptor.

Authors:  Eberhard Ritz
Journal:  Pediatr Nephrol       Date:  2004-10-27       Impact factor: 3.714

3.  Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia.

Authors:  B Festen-Spanjer; C M Haring; J B Koster; A H Mudde
Journal:  Clin Endocrinol (Oxf)       Date:  2007-09-04       Impact factor: 3.478

4.  Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis.

Authors:  S H Pearce; C Wooding; M Davies; S E Tollefsen; M P Whyte; R V Thakker
Journal:  Clin Endocrinol (Oxf)       Date:  1996-12       Impact factor: 3.478

5.  Localization of the extracellular Ca2+/polyvalent cation-sensing protein in rat kidney.

Authors:  D Riccardi; A E Hall; N Chattopadhyay; J Z Xu; E M Brown; S C Hebert
Journal:  Am J Physiol       Date:  1998-03

6.  Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor.

Authors:  H J L M Timmers; M Karperien; N A T Hamdy; H de Boer; A R M M Hermus
Journal:  J Intern Med       Date:  2006-08       Impact factor: 8.989

7.  Middle-term use of Cinacalcet in paediatric dialysis patients.

Authors:  Caroline Platt; Carol Inward; Mary McGraw; Jan Dudley; Jane Tizard; Christine Burren; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

8.  Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.

Authors:  Jenny Ying Lin Lu; Yuhua Yang; Gilles Gnacadja; Arthur Christopoulos; Jeff D Reagan
Journal:  J Pharmacol Exp Ther       Date:  2009-09-16       Impact factor: 4.030

Review 9.  Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues.

Authors:  L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-07       Impact factor: 2.894

10.  Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M R Pollak; E M Brown; Y H Chou; S C Hebert; S J Marx; B Steinmann; T Levi; C E Seidman; J G Seidman
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

View more
  18 in total

Review 1.  The calcium-sensing receptor in bone--mechanistic and therapeutic insights.

Authors:  David Goltzman; Geoffrey N Hendy
Journal:  Nat Rev Endocrinol       Date:  2015-03-10       Impact factor: 43.330

Review 2.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

3.  Familial hypocalciuric hypercalcemia: new mutation in the CASR gene converting valine 697 to methionine.

Authors:  Cristina Aparicio López; Pilar Anton-Martin; Belén Gil-Fournier; Soraya Ramiro-León; Gustavo Pérez-Nanclares; Guiomar Pérez de Nanclares; Beatriz Martínez Menéndez; Luis Castaño
Journal:  Eur J Pediatr       Date:  2011-06-04       Impact factor: 3.183

Review 4.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

5.  Cinacalcet as adjunctive therapy in pseudohypoparathyroidism type 1b.

Authors:  Tarak Srivastava; Jeffrey Krudys; Neil J Mardis; Judith Sebestyen-VanSickle; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2015-12-01       Impact factor: 3.714

Review 6.  Use of calcimimetics in children with normal kidney function.

Authors:  Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2018-03-19       Impact factor: 3.714

Review 7.  Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.

Authors:  Gerda E Breitwieser
Journal:  Mol Endocrinol       Date:  2012-06-28

8.  Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.

Authors:  Aura J Arenas Morales; Marissa J DeFreitas; Chryso P Katsoufis; Wacharee Seeherunvong; Jayanthi Chandar; Gaston Zilleruelo; Michael Freundlich; Carolyn L Abitbol
Journal:  Pediatr Nephrol       Date:  2018-09-10       Impact factor: 3.714

Review 9.  Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway.

Authors:  Fadil M Hannan; Mie K Olesen; Rajesh V Thakker
Journal:  Br J Pharmacol       Date:  2017-12-11       Impact factor: 8.739

Review 10.  Therapeutic Opportunities of Targeting Allosteric Binding Sites on the Calcium-Sensing Receptor.

Authors:  Jiayin Diao; Aaron DeBono; Tracy M Josephs; Jane E Bourke; Ben Capuano; Karen J Gregory; Katie Leach
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.